4 assets in DiGeorge Syndrome

Therapeutic assets addressing DiGeorge Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Alemtuzumab DiGeorge Syndrome	Paul Szabolcs	P2	CCC (53)
Fludarabine DiGeorge Syndrome	Paul Szabolcs	P2	CCC (53)
Melphalan DiGeorge Syndrome	Paul Szabolcs	P2	CCC (53)
Thiotepa DiGeorge Syndrome	Washington University School of Medicine	P2	CCC (53)